The Advent of Automated, Gene-Engineered TIL Manufacturing
Tumor-infiltrating leukocytes (TILs) tend to be manufactured at small scale in labs using manual, bespoke processes to account for inconsistent starting materials and conditions. As TIL-based therapeutics move to clinical scale, however, automation and the reproducibility and efficiency it provides become invaluable.
A handful of companies are working to automate the TIL production process. The latest, Terumo Blood and Cell Technologies (Terumo BCT), is using its Quantum Flex
Cell Expansion System to automate the production of genetically engineered TILs in partnership with TrAMPoline Pharma and the University of Colorado.
“Automation could help bridge the gap between development in the lab and clinical scale by utilizing the same scalable technology for both phases to ultimately preserve product quality along the development pipeline,” Mindy Miller, PhD, head of cell therapy scientific development at Terumo BCT, tells GEN.
The challenge is that TILs are produced from T cells that have infiltrated tumors. These T cells typically don’t expand as efficiently as T cells found in the bloodstream, so vastly greater quantities of T cells are needed to produce potent doses.
“We recognized that a process dependent on extensive manual handling would inevitably limit clinical translation,” Eduardo Davila, PhD, professor of medicine at the University of Colorado, and co-founder and CSO at TrAMPoline Pharma, adds. His research into T cell infiltration is the basis for TrAMPoline Pharma’s TIL program. This collaboration “aims to make engineered TIL manufacturing more reproducible and efficient while preserving the cells’ tumor-fighting capabilities.”
To that end, Davila says, “We are focusing on standardized culture conditions, automated feeding, and fewer manual manipulations. Our goal is to preserve engineered TIL identity, viability, and antitumor function.”
The automation process is being undertaken in phases. The first step is to validate automated cell expansion against the existing process. Then, additional steps will be validated and integrated into the workflow.
“We anticipate a substantial reduction in hands-on labor and expedited TIL expansion. Whether total manufacturing time also decreases—and by how much—must be established experimentally,” Davila says. But, Miller adds, “it is still being evaluated.”
Today, it takes about three weeks to manufacture TILs. While neither Miller nor Davila will suggest a target timeframe for engineered TIL manufacturing within this partnership, Davila says, “We anticipate more consistent yield, fewer manual interventions, and greater manufacturing capacity, with the potential to reduce cost and turnaround time.”
Additionally, he continues, “We will evaluate these gains alongside gene transfer efficiency, viability, phenotype, and tumor-specific killing. Improved potency is an outcome to test, rather than assume.”
Miller emphasizes, “Our focus is adapting automation to the particular requirements of engineered TILs.”
The post The Advent of Automated, Gene-Engineered TIL Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
